Impact of Natriuretic Peptide and Prior Hospitalization in Patients With Severe Mitral Regurgitation: COAPT Trial
Circulation: Cardiovascular Interventions · 2025
DOI: 10.1161/circinterventions.125.015192 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Circulation: Cardiovascular Interventions, 2025. Verfasst von Sachin S Goel und 13 weiteren Autor:innen. Beteiligte Einrichtung: Houston Methodist Hospital, TX (S.S.G., A.G., S.H.L., M.J.R., N.S.K.). Hauptthemen laut MEDLINE: Cardiac Catheterization, Heart Failure, Heart Valve Prosthesis Implantation, Mitral Valve Insufficiency. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 17 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: The clinical significance of elevated baseline natriuretic peptide level and prior heart failure hospitalization (HFH) within the prior year in mitral transcatheter edge-to-edge repair outcomes is unclear. This analysis examined the impact of BNP (B-type natriuretic peptide) or NT-proBNP (N-terminal pro-B-type natriuretic peptide) and prior HFH on outcomes in patients with severe secondary mitral regurgitation. METHODS: The COAPT trial (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation) was a randomized controlled trial of subjects assigned to mitral valve transcatheter edge-to-edge repair with the MitraClip device versus guideline-directed medical therapy alone. COAPT patients were grouped by BNP/NT-proBNP levels and prior HFH within 1 year: (1) Mild heart failure (HF): no prior HFH with BNP/NT-proBNP
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Houston Methodist Hospital, TX (S.S.G., A.G., S.H.L., M.J.R., N.S.K.).
- Vanderbilt University Medical Center, Nashville, TN (J.A.L.).
- The Ohio State University Wexner Medical Center, Columbus (W.T.A.).
- Los Robles Regional Hospital, Thousand Oaks, CA (S.K.).
- Cleveland Clinic, OH (S.R.K.).
- University of Virginia School of Medicine, Charlottesville (D.S.L.).
ORCID-Profile: Sachin S Goel, JoAnn Lindenfeld, William T Abraham, Samir R Kapadia, Neal S Kleiman, Michael J Mack, Gregg W Stone
Zitieren
APA
Goel, S. S., Guha, A., Lindenfeld, J., Abraham, W. T., Kar, S., Kapadia, S. R., Little, S. H., Lim, D. S., Reardon, M. J., Kleiman, N. S., Aiyer, J., Kotinkaduwa, L. N., Mack, M. J., & Stone, G. W. (2025). Impact of Natriuretic Peptide and Prior Hospitalization in Patients With Severe Mitral Regurgitation: COAPT Trial. Circulation: Cardiovascular Interventions. https://doi.org/10.1161/circinterventions.125.015192
Vancouver
Goel SS, Guha A, Lindenfeld J, Abraham WT, Kar S, Kapadia SR, et al. Impact of Natriuretic Peptide and Prior Hospitalization in Patients With Severe Mitral Regurgitation: COAPT Trial. Circulation: Cardiovascular Interventions. 2025. doi:10.1161/circinterventions.125.015192
BibTeX
@article{Goel2025,
author = {Goel, Sachin S and Guha, Ashrith and Lindenfeld, JoAnn and Abraham, William T and Kar, Saibal and Kapadia, Samir R and Little, Stephen H and Lim, D Scott and Reardon, Michael J and Kleiman, Neal S and Aiyer, Janani and Kotinkaduwa, Lak N and Mack, Michael J and Stone, Gregg W},
title = {Impact of Natriuretic Peptide and Prior Hospitalization in Patients With Severe Mitral Regurgitation: COAPT Trial},
journal = {Circulation: Cardiovascular Interventions},
year = {2025},
doi = {10.1161/circinterventions.125.015192}
}
EUVIMED